Response to letter: “Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by Suzuki et al.

We read with great interest the letter titled “Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule” by Suzuki et al. and appreciated the aspects that they emphasized. We agree that real-world data about the effect on migraine of switching betwe en anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) based on the dosing schedule should be investigated further and we would like to respond to their letter by providing detailed information on monthly migraine day (MMD) response rates, accompanying symptoms, and side effe cts from our recent publication.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research